Why post-injection guidance is sparse — and why it still matters

Leaving the clinic with a hip biological injection done, most patients face the same practical question: what should I actually do now? The honest answer from the published literature is that nobody has yet agreed on a definitive answer.

A 2024 scoping review examined 200 intra-articular orthobiologic studies and found that 37.5% reported no post-procedure protocol whatsoever. Of the studies that did include guidance, fewer than 38.4% described any rehabilitation component, and fewer than 22% specified weight-bearing restrictions. The most consistently documented instructions were pharmacological: NSAID avoidance appeared in 91.2% of relevant protocols and corticosteroid restriction in 84.8%. Both reflect a biological rationale — these agents can suppress the very inflammatory response that drives tissue repair — rather than any RCT-derived consensus on timing or activity level.

For hip injections specifically — platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and microfragmented adipose tissue (mFAT) — no standardised return-to-activity protocol has yet been published. That absence makes a structured approach more important, not less. Without a framework, patients either rest too long and lose the conditioning that supports recovery, or return to loading too early and risk compromising the biological environment the injection is intended to create.

The pathway set out here is clinically derived and grounded in biological principles. It is not a validated RCT protocol, and it should be read as decision-support rather than a substitute for individual clinical assessment.

What is happening in the hip joint after a biological injection

Each of the three agents works by seeding a repair environment inside the hip joint rather than directly rebuilding tissue. PRP delivers a concentrated payload of growth factors derived from the patient's own blood, signalling local cells to proliferate and reduce inflammation. BMAC introduces mesenchymal stem cells harvested from the iliac crest of the pelvis, which can differentiate and support cartilage repair processes. mFAT preserves adipose-derived stromal cells and their associated growth factors, contributing anti-inflammatory and paracrine signals to the joint environment. In each case the material needs time and favourable local conditions to act — it cannot do so if those conditions are immediately disrupted.

Two common medications work against this process. NSAIDs such as ibuprofen suppress the controlled inflammatory signalling that underpins tissue repair; taken in the days after injection, they may blunt the very response the orthobiologic is designed to promote. A corticosteroid injection into the same joint during this window carries a similar risk, suppressing cellular activity at precisely the moment it is needed.

The hip adds a mechanical dimension that the shoulder or wrist do not share: it carries the full weight of the body with every step. Returning to high loading too soon may physically disperse the injectate before it has had the opportunity to integrate with the surrounding synovial tissue and cartilage. The initial period of relative rest is therefore a therapeutic step — it protects the biological environment the injection is working to create, even if it does not guarantee that repair will follow.

The first two weeks: what to do and what to avoid

During the first two weeks, the priority is protecting the repair environment the injection has created. Practically, this means treating the hip with deliberate care — not immobility, but purposeful restraint.

What to do

• Keep moving gently. Light walking on flat ground is appropriate and helpful. Aim to change position regularly; prolonged static sitting or standing increases hip loading without therapeutic benefit.
• Manage pain with paracetamol if needed, at standard doses. Check any other medication with your clinician before the procedure.
• Rest the donor site if you had BMAC. The iliac-crest harvest point — at the back of the pelvis — will have its own discomfort, separate from the hip itself. This is expected and typically settles within a few days; it should not be confused with a hip response.

What to avoid

• NSAIDs (ibuprofen and similar) and corticosteroid injections into the hip — for the reasons established above.
• High-impact activity, loaded gym work, running, cycling at resistance, or any sustained single-leg loading of the injected hip.

Driving and light work

Return to driving and desk-based work depends on comfort and your ability to control the hip, not on a fixed calendar date. Most patients find this straightforward within the first two weeks; physically demanding roles take longer.

When to seek advice

Increasing warmth, significant swelling, fever, or worsening pain after the first 48 hours warrant prompt contact with the clinical team — these are uncommon but should be assessed rather than managed with watchful waiting.

Rebuilding movement and load: the progressive rehabilitation phase

Cartilage has no direct blood supply; it depends on the rhythmic compression and decompression of joint movement to draw in nutrients and expel waste products. This is the mechanical rationale for graduated loading from approximately week two onwards — complete rest beyond the initial protection phase is not neutral, it is counterproductive. The goal shifts from protecting the repair environment to actively supporting it through controlled movement.

The progression follows a three-stage arc. The first stage — joint protection — centres on gentle hip range-of-motion exercises, level-surface walking with comfortable footwear, and aquatic exercise where available. Water reduces effective joint load while allowing the muscles around the hip to begin working again. The second stage introduces progressive resistance: hip abductor and gluteal strengthening, progressing from supported to unsupported positions, and core stability work to distribute load across the pelvis rather than concentrating it at the joint. The third stage — functional integration — applies those gains to real-world movement patterns: stairs, uneven ground, and longer walking distances.

A 2023 RCT of 60 hip OA patients found that a structured 12-week programme combining hip and core strengthening significantly outperformed hip-only exercise on 6-minute walk test distance, NPRS pain scores, WOMAC function, and core stability measures. This supports integrated loading — not isolated hip work — as the rehabilitation standard.

Crucially, a 2024 study demonstrated that combining an intra-articular injection with a structured 12-week criteria-based programme achieved sustained PROM improvements and 93% patient satisfaction at 24 months, with only 32% ultimately requiring surgery — substantially better than injection alone.

Advancement through each stage is criteria-gated, not calendar-driven. A patient moves forward when they demonstrate adequate hip range of motion, meet strength thresholds for the hip abductors, show acceptable limb symmetry — meaning the injected leg is performing comparably to the other — and can manage loading without a significant pain flare. Time is a rough guide; these objective markers are the actual gate.

Criteria for returning to full activity — and how they differ by injection type

These criteria are clinically derived and biologically informed — no published hip-specific RCT has validated them as a discrete return-to-activity framework after PRP, BMAC, or mFAT injection, and they are best used as a principled clinical compass rather than a certified protocol.

Core return-to-activity criteria

Five objective markers gate progression toward full activity:

• Hip range of motion approaching the contralateral side to a clinically acceptable margin.
• Hip abductor strength at a limb symmetry index of at least 70–80% relative to the non-injected leg.
• Single-leg stance without Trendelenburg sign — pelvis level under load, indicating adequate abductor control.
• Pain-free weight-bearing throughout the stance phase of level walking.
• Functional task completion: stairs, sit-to-stand from a standard chair, and sustained level walking at a comfortable pace.

Time is a rough guide; meeting these markers is the actual gate.

How expectations differ by injection type

mFAT carries the most direct hip-specific outcome data. A three-year follow-up of 71 patients receiving a single 4 mL ultrasound-guided injection found that 28 of 55 required no further intervention, with an average Oxford Hip Score gain of 6.9 points. Benefit was concentrated in patients with a pre-injection OHS between 30 and 48; return-to-activity milestones should therefore be anchored against the individual's pre-injection baseline rather than a population average.

BMAC adds a safety-monitoring dimension that the other agents do not require. In femoral head osteonecrosis — one of its primary hip indications — 30% of patients progressed to Stage III despite meaningful improvement in pain and Harris Hip scores. Meeting the functional criteria above clears a patient for graduated activity; it does not substitute for scheduled radiological review of the femoral head.

PRP has the weakest and most contested hip-specific evidence of the three. A 2024 double-blind RCT found no significant advantage over saline placebo on VAS, WOMAC, or SF-36 at six months; a separate review found reporting spin in all 15 existing systematic reviews of PRP for hip OA, predominantly inflating apparent benefit. Criteria-based progression matters more here precisely because tissue-level repair cannot be assumed — functional markers become the only reliable basis for deciding when to advance.

When progress stalls and what to do next

Stalling is clinical information, not failure. If a patient has followed a graduated rehabilitation programme and is still not meeting the functional criteria milestones by 12 to 16 weeks, that is a clear prompt for clinical review — not a reason to extend passive waiting.

The trigger points differ by agent:

• mFAT: persistent non-response at three to six months should prompt reassessment of OA staging. If imaging and symptoms now align with more advanced disease, a frank discussion about surgical options is appropriate rather than repeating injection.
• BMAC in avascular necrosis of the femoral head: scheduled radiological monitoring is part of the pathway regardless of how symptoms are tracking. Symptom improvement does not exclude ongoing disease progression — published series have shown Stage III advancement in patients who reported meaningful pain and functional gains. Imaging review is a safety matter, not an optional extra.
• PRP: non-response warrants re-evaluation of the underlying diagnosis and OA grade. Given the contested evidence base for PRP in hip OA, functional improvement is the only reliable signal — and its absence is meaningful.

In all cases, the criteria-based framework is designed to surface problems early. A patient who is not progressing deserves timely reassessment, not extended uncertainty.

1. [1] Postprocedure protocols after intraarticular orthobiologic injections—A scoping review. (2024). https://doi.org/10.1002/pmrj.13271 https://doi.org/10.1002/pmrj.13271
2. [2] Mid-term Results of Core Decompression Combined With Bone Marrow Aspirate Concentrate (BMAC) Injection for Early Osteonecrosis of the Femoral Head. (2025). https://doi.org/10.7759/cureus.94788 https://doi.org/10.7759/cureus.94788
3. [3] The role of rehabilitation after regenerative and orthobiologic procedures for the treatment of tendinopathy: a systematic review. (2018). https://doi.org/10.2217/rme-2017-0110 https://doi.org/10.2217/rme-2017-0110
4. [4] Is intra-articular injection of autologous micro-fragmented adipose tissue effective in hip osteoarthritis? A three year follow-up. (2022). https://doi.org/10.1007/s00264-022-05611-x https://doi.org/10.1007/s00264-022-05611-x
5. [5] Core muscle strengthening exercises in the management of hip osteoarthritis: outcomes of a 12-week programme. (2023). https://doi.org/10.1080/21679169.2023.2194319 https://doi.org/10.1080/21679169.2023.2194319
6. [6] Effect of platelet-rich plasma injections versus placebo on pain and quality of life in patients with hip osteoarthritis: A double-blind, randomized clinical trial. (2024). https://doi.org/10.5606/tftrd.2024.13855 https://doi.org/10.5606/tftrd.2024.13855
7. [7] Patient Outcomes Are Not Improved by Platelet-Rich Plasma Injection Onto the Capsule at the Time of Closure During Hip Arthroscopy for Femoroacetabular Impingement Syndrome. (2023). https://doi.org/10.1016/j.asmr.2023.100816 https://doi.org/10.1016/j.asmr.2023.100816
8. [8] Orthobiologics for the Hip Region: A Narrative Review. (2020). https://doi.org/10.1002/pmrj.12327 https://doi.org/10.1002/pmrj.12327
9. [9] Reporting Bias is Highly Prevalent in Systematic Reviews and Meta-Analyses of Platelet Rich Plasma Injections for Hip Osteoarthritis. (2024). https://doi.org/10.1016/j.asmr.2023.100851 https://doi.org/10.1016/j.asmr.2023.100851
10. [10] PRP Is Not Associated With Improved Outcomes Following Hip Femoroacetabular Impingement Surgery: Very Low-Quality Evidence Suggests Hyaluronic Acid and Cell-Based Therapies May Be Beneficial—A Systematic Review. (2022). https://doi.org/10.1016/j.asmr.2022.05.002 https://doi.org/10.1016/j.asmr.2022.05.002